These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37360768)

  • 21. RET signaling pathway and RET inhibitors in human cancer.
    Regua AT; Najjar M; Lo HW
    Front Oncol; 2022; 12():932353. PubMed ID: 35957881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
    Zheng H; Chen ZS; Li J
    Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RET Inhibitors in Non-Small-Cell Lung Cancer.
    Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precision oncology for
    Verrienti A; Grani G; Sponziello M; Pecce V; Damante G; Durante C; Russo D; Filetti S
    Front Oncol; 2022; 12():992636. PubMed ID: 36091144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current perspectives on the management of patients with advanced
    Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
    Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
    Clark L; Fisher G; Brook S; Patel S; Arkenau HT
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
    Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
    Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development.
    Thein KZ; Myat YM; Park BS; Panigrahi K; Kummar S
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State-of-the-Art Strategies for Targeting
    Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F
    J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management of
    Stinchcombe TE
    Ther Adv Med Oncol; 2020; 12():1758835920928634. PubMed ID: 32782485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
    Saha D; Ryan KR; Lakkaniga NR; Acharya B; Garcia NG; Smith EL; Frett B
    J Med Chem; 2021 Aug; 64(16):11747-11773. PubMed ID: 34402300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A contemporary review of rearranged during transfection-selective inhibitors.
    Liu AW; Liang C; Lee CS
    J Oncol Pharm Pract; 2022 Jan; 28(1):175-184. PubMed ID: 34590525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.
    Nardo M; Gouda MA; Nelson BE; Barreto CMN; Slade JH; Poullard A; Zafereo M; Hu MI; Cabanillas ME; Subbiah V
    Cell Rep Med; 2023 Dec; 4(12):101332. PubMed ID: 38118420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decade in review: a new era for RET-rearranged lung cancers.
    Choudhury NJ; Drilon A
    Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review.
    Chen J; Xu C; Lv J; Lu W; Zhang Y; Wang D; Song Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):895-908. PubMed ID: 37197619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.